The results of population pharmacokinetic modeling of pyrotinib in patients with HER2-positive breast cancer suggest that clinical medical staff should pay attention to the liver function of patients with abnormal serum total protein and be alert to the occurrence of hepatotoxicity. This evidence concerns the gene ERBB2 and breast carcinoma.